Long-term follow-up of people with sickle cell disease treated with BEAM-101
Follows people with sickle cell disease for years after receiving BEAM-101.
Key facts
- Who runs it
- Beam Therapeutics Inc.
- Where
- Atlanta, Birmingham, Boston, Charleston, Cleveland, Detroit, Hackensack, Jacksonville, Memphis, Milwaukee, Minneapolis, Nashville, New York, Philadelphia, Phoenix, and St Louis, United StatesSee the 17 sites
- Trial code
- Registry title
- A Long-term Follow-up Study in Patients Who Received BEAM-101
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 15 Dec 2025
- Expected to end
- 12 Feb 2043
- Type of study
- Observational
- Treatments tested
- Long-Term Follow-up Study of patients who received BEAM-101
- Record updated
- 28 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who received BEAM-101 in the earlier study BTX-AUT-001 and are finishing that study. They will be followed for 13 more years.
- Age
- 14 Years to 37 Years
- Sex
- All sexes can join.
- Earlier treatment
- Must have received BEAM-101 in Study BTX-AUT-001 and be completing that study's end-of-study visit.
Main reasons for not taking part
- There are no exclusion criteria for this study.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Have received BEAM-101 in Study BTX-AUT-001 and are in the process of completing that study's end-of-study (EOS) visit
- Provide signed, written informed consent according to local institutional review board (IRB)/independent ethics committee (IEC) and institutional requirements
Who cannot take part
- There are no exclusion criteria for this study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 37 years old?
Where in United States
- Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- EglestonAtlanta, United StatesNot yet recruiting
- University of Alabama at BirminghamBirmingham, United StatesNot yet recruiting
- Boston Children's HospitalBoston, United StatesTaking people
- Medical University of South CarolinaCharleston, United StatesNot yet recruiting
- The Clevland Clinic FoundationCleveland, United StatesNot yet recruiting
- University Hospitals Clevland Medical CenterCleveland, United StatesNot yet recruiting
- Henry Ford Cancer CenterDetroit, United StatesNot yet recruiting
- Hackensack University Medical CenterHackensack, United StatesNot yet recruiting
- Mayo Clinic FloridaJacksonville, United StatesNot yet recruiting
- St. Jude Children's Research HospitalMemphis, United StatesNot yet recruiting
- Medical College of WisconsinMilwaukee, United StatesNot yet recruiting
- University of MinnesotaMinneapolis, United StatesNot yet recruiting
- The Children's Hospital at TriStar CentennialNashville, United StatesNot yet recruiting
- Columbia University Irving Medical CenterNew York, United StatesNot yet recruiting
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesNot yet recruiting
- Phoenix Children s HospitalPhoenix, United StatesNot yet recruiting
- Washington University School of Medicine in St. LouisSt Louis, United StatesNot yet recruiting
About the trial
What the trial wants to find out
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).
The group in the trial
- BTX-101-002 Long-term Follow-up on Patients who received BEAM-101
All participants who received BEAM-101 in the BTX-AUT-001 trial will be asked to participate in this long-term follow-up study
Treatment: Long-Term Follow-up Study of patients who received BEAM-101
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Long-term Follow-up Study in Patients With Hemoglobinopathy Who Received Autologous CD34+ Edited Hematopoietic Stem Cells
- Plain-language title
- Long-term follow-up of people with sickle cell disease treated with BEAM-101Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07373639, who can take part
- Record updated
- 28 January 2026